您的位置: 专家智库 > >

国家自然科学基金(30973006)

作品数:3 被引量:6H指数:2
相关作者:徐丹枫滕竞飞李尧崔心刚刘玉杉更多>>
相关机构:第二军医大学更多>>
发文基金:国家自然科学基金更多>>
相关领域:医药卫生生物学更多>>

文献类型

  • 3篇中文期刊文章

领域

  • 2篇医药卫生
  • 1篇生物学

主题

  • 2篇前列腺
  • 2篇前列腺癌
  • 2篇腺癌
  • 1篇蛋白
  • 1篇前列腺癌干细...
  • 1篇肿瘤
  • 1篇肿瘤干细胞
  • 1篇细胞
  • 1篇干细胞
  • 1篇癌干细胞
  • 1篇靶蛋白
  • 1篇PATIEN...
  • 1篇EVALUA...
  • 1篇LAPARO...
  • 1篇MIR-12...
  • 1篇EXTRAP...

机构

  • 2篇第二军医大学

作者

  • 2篇徐丹枫
  • 1篇高轶
  • 1篇任吉忠
  • 1篇姚亚成
  • 1篇滕竞飞
  • 1篇刘玉杉
  • 1篇崔心刚
  • 1篇李尧

传媒

  • 1篇临床泌尿外科...
  • 1篇Chines...
  • 1篇现代生物医学...

年份

  • 1篇2012
  • 2篇2011
3 条 记 录,以下是 1-3
排序方式:
miR-126调控前列腺癌机制研究
2011年
miR-126通过靶向作用于表皮生长因子域7(EGFL7)、同源框A9(HOXA9)、胰岛素受体底物-1(IlLS-1)、p85-B基因等,在转录后水平调控靶基因表达,在肿瘤形成中起重要作用。前列腺癌细胞中高表达miR-126,能明显下调VEGF-A、EGLF7、HOXA9、VCAM-l等与肿瘤生长、转移密切相关的蛋白分子。miR-126作为抑癌因子,在多种肿瘤中均下调。其抑癌作用及机制在肺癌、白血病、乳腺癌、宫颈癌等中均已得到证实。本课题拟对miR-126调控前列腺癌机制做一综述。
李尧徐丹枫崔心刚刘玉杉任吉忠姚亚成高轶
关键词:MIR-126前列腺癌靶蛋白
前列腺癌干细胞研究进展被引量:2
2011年
前列腺癌是中老年男性常见的恶性肿瘤,发病率位居发达国家男性恶性肿瘤之首。目前前列腺癌的发生、发展、转移、复发等机制仍不甚明确,本文从肿瘤干细胞理论的角度对前列腺癌的细胞起源、疾病进展、肿瘤转移、复发以及前列腺癌干细胞的分离鉴定作一综述。
滕竞飞徐丹枫
关键词:干细胞前列腺癌肿瘤干细胞
Evaluating the oncologic outcomes in 152 patients undergoing extraperitoneal laparoscopic radical prostatectomy被引量:4
2012年
Background Although many midterm oncologic data have been reported for extraperitoneal laparoscopic radical prostatectomy (ELRP) in western countries, few oncologic data of the extraperitoneal procedure was published in China. The aim of the study was to evaluate the oncologic outcomes of patients treated with ELRP in China.Methods From January 2005 to March 2010, a total of 152 consecutive patients diagnosed with clinically localized prostate cancer were included in this study and treated with ELRP. The patients were staged according to the TNM (tumor, nodes, metastases) system. Median and mean postoperative follow-up were 28.1 months and 27.0 months, respectively. The patients were retrospectively analyzed for progression-free survival.Results One hundred and twelve cases (73.7%) were postoperatively diagnosed as pT2 in, and 40 cases (26.3%) as pT3. Positive lymph nodes were shown in 5 patients (3.3%). Gleason score was 〈7 in 49 men (32.2%), 7 in 69 men (45.4%), and 〉7 in 34 men (22.4%). Positive surgical margins (PSM) were observed in 15 patients (9.9%), which included 32.0% of all pT3a cases and 46.7% of all pT3b cases, respectively. The overall prostate-specific antigen recurrence-free survival rate was 86% in all patients. The recurrence-free survival rates were 91.8% and 62.2% in pT2N0 patients and pT3N0 patients, respectively. Preoperative prostate-specific antigen, surgical margins, tumor stage, and lymph nodal status were identified as independent predictors of biochemical recurrence-free survival using multivariate Cox proportional hazard model. Conclusions ELRP is a precise, safe and effective procedure at this particular Chinese institution. The prognostic power of prostate-specific antigen relapse after ELRP is not identical to that described previously with transperitoneal or open retropubic approaches.
LI Xun-gangZHANG Dong-xuCUI Xin-gangXU Dan-fengHONG YiLI YaoGAO YiLIU Yu-shanYIN LeiQU Fa-junWANG Jun-kaiCHEN MingCHEN JieCHEN LuWANG Kai
关键词:LAPAROSCOPY
共1页<1>
聚类工具0